2. Academic Validation
  3. Cysteine-modified PEGylated nanoparticles for targeted delivery of methylprednisolone to pancreatitis

Cysteine-modified PEGylated nanoparticles for targeted delivery of methylprednisolone to pancreatitis

  • Eur J Pharm Biopharm. 2024 Jan 8:114179. doi: 10.1016/j.ejpb.2024.114179.
Jianbo Li 1,  Ertai Ye 1,  Jingwen Huang 1,  Meng Xu 2,  Jieke Zhang 3,  Junrong Zhang 4,  Huijie Cai 3,  Jinjie Zhang 5
Affiliations

Affiliations

  • 1 Henan Key Laboratory for Pharmacology of Liver Diseases, BGI College & Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.
  • 2 Henan Key Laboratory for Pharmacology of Liver Diseases, BGI College & Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China; School of Basic Medical Science, Academy of Medical Science, Zhengzhou University, Zhengzhou 450001, China.
  • 3 Henan Key Laboratory of Targeting Therapy and Diagnosis for Critical Diseases, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.
  • 4 Department of Pathogen Biology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450001, China.
  • 5 Henan Key Laboratory of Targeting Therapy and Diagnosis for Critical Diseases, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China. Electronic address: [email protected].
PMID: 38199584 DOI: 10.1016/j.ejpb.2024.114179
Abstract

The timely suppression of inflammatory mediator production and mitigation of their effects on pancreatic acinar cells are crucial for the successful management of acute pancreatitis. To achieve effective treatment, we present a novel approach utilizing cysteine modified PEG nanoparticles for both precise accumulation at the site of pancreatitis and specific targeting of acinar cells. Methylprednisolone, a nonsteroidal anti-inflammatory drug, was tailored to enhance its circulation time in the bloodstream, preferentially accumulate in the pancreas and enhance cell uptake efficiency by acinar cells through specifically targeting L-Type amino acid transporter 1. The nanosystem significantly downregulated pro-inflammatory cytokines in plasma, resulting in the effective suppression of inflammation in acinar cells within an acute pancreatitis rat model. The utilization of the dual targeted therapy strategy holds considerable potential for the clinical management of pancreatitis.

Keywords

Acinar cell; Amino acid transporter; Anti-inflammatory; Cysteine; Pancreatitis.

Figures
Products